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We used an epitope-tagging approach to determine the ratio of Gag (structural) to Vpr (nonstructural) in the virus particles
directed by human immunodeficiency virus type 1. For this purpose, chimeric Gag and Vpr expression plasmids were
constructed with the Flag epitope (DYKDDDDK), and the sequences corresponding to the chimeric protein were introduced
into human immunodeficiency virus type 1 proviral DNA (NL4-3) to determine the ratio in the virus particles when these
proteins are expressed in cis. In addition, NL4-3 DNA was modified to disrupt Vpr synthesis to determine the extent of
incorporation of Vpr-FL when it is expressed in trans through a heterologous promoter. The analysis of virus particles
generated by transfection of proviral DNA into RD cells indicated that (1) the ratio of Gag to Vpr in virus particles, when Vpr-FL
is expressed in cis (in the context of proviral DNA), is in the range of 150–200:1 (14–18 molecules of Vpr per virion) and (2)
the expression of Vpr-FL in trans showed efficient incorporation with a Gag to Vpr ratio of 5–7:1 (392–550 molecules of Vpr).
These results suggest that the presence of the same epitope on different viral proteins may provide an accurate comparison
of these proteins in the virus particles. © 2000 Academic Press
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oINTRODUCTION
Genetic analysis of the lentivirus family of retroviruses
has revealed that the genomes of these viruses are
complex compared with simple retroviruses (Levy, 1998).
Specifically, the genome of human immunodeficiency
virus type 1 (HIV-1) has been shown to code for six
auxiliary proteins in addition to the Gag, Pol, and Env
structural proteins (Luciw, 1996; Levy, 1998). With respect
to the viral morphogenetic events, lentiviruses follow the
pathway of the type C retroviruses (Hunter, 1994). Char-
acteristically, Gag and Gag-Pol proteins are synthesized
in the cytoplasm and transported to the cell membrane,
and viral assembly occurs at the cell membrane of the
infected cells. Although the mechanism of transport of
Gag and Gag-Pol proteins to the cell membrane is not
clear, the Env protein reaches the cell membrane
through the secretory pathway (Hunter, 1994). This sce-
nario suggests that the incorporation of viral proteins into
the virus particles may require their interaction either in
the cytoplasm or at the cell membrane (Hunter, 1994;
Cohen et al., 1996).
Biochemical analysis of HIV-1 particles revealed the
presence of several nonstructural proteins of viral origin
in the virus particles (Cullen, 1998); these include Vif, Vpr,
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364and Nef, which are present in different amounts in the
virus particles (Levy, 1998). It has been shown that both
Vif and Nef exhibit nonspecific incorporation into heter-
ologous retrovirus particles (Cullen, 1998; Levy, 1998) in
addition to the particles directed by HIV-1 Gag. A recent
study reported that Vif is not present in highly purified
virions (Dettenhofer and Yu, 1999). On the other hand, the
incorporation of Vpr into the virus particles has been
shown to be specific, involving distinct domains in HIV-1
Gag (Cullen, 1998; Emerman, 1996; Levy, 1998). To ex-
plore the mechanism or mechanisms governing the in-
corporation of nonstructural protein or proteins into the
virus particles, we have been conducting studies on Vpr.
In addition to its essential role in the infection of macro-
phages by HIV-1 (Emerman, 1996), the characteristic
features of Vpr include cell cycle arrest at the G2 stage
(Emerman, 1996; He et al., 1995; Jowett et al., 1995; Re et
l., 1995; Rogel et al., 1995), nuclear localization (Emer-
an, 1996; Zhao et al., 1994a), participation in the trans-
ort of the preintegration complex (Heinzinger et al.,
994), cation channel activity (Piller et al., 1996), and
nteraction with several candidate cellular proteins (Bou-
amdan et al., 1996; Fouchier et al., 1998; Gragerov et al.,
998; Refaeli et al., 1995; Stark and Hay, 1998; Tung et al.,
997; Zhao et al., 1994a,b). Work from our laboratory and
thers showed the importance of putative helical do-
ains present in Vpr for its incorporation into virus par-
icles (Di Marzio et al., 1995; Luo et al., 1998; Mahalingam
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365STOICHIOMETRY OF VIRAL PROTEINSet al., 1995; Nie et al., 1998; Subbramanian et al., 1998;
Yao et al., 1995). Furthermore, evidence was also pre-
sented for the interaction of Vpr and Gag in the cells,
which may be the basis for its incorporation into virus
particles (Lavallee et al., 1994). Regarding Gag, a role for
the p6 region in the incorporation of Vpr into the virus
particles has been demonstrated through deletion and
the transfer of this domain to an unrelated Moloney
murine leukemia virus Gag (Checroune et al., 1995;
Kondo et al., 1995; Lu et al., 1993, 1995; Paxton et al.,
1993).
Despite a wealth of data available on Vpr, the informa-
tion regarding the amount of Vpr incorporated into the
virus particles is not clear. This information may be
useful for elucidating the mechanism or mechanisms
involved in the incorporation of Vpr into the virus parti-
cles and for developing Vpr as an analytical and thera-
peutic agent. In this regard, a related protein designated
Vpx (Tristem et al., 1992) has been shown to be present
in HIV-2 virions in equimolar quantities to that of p27 of
Gag (Henderson et al., 1988). To determine the amount of
Vpr incorporated into HIV-1 virus particles, we used an
epitope-tagging approach on Gag and Vpr involving Flag
as the epitope (Chubet and Brizzard, 1996). Combining
the sensitive p24 antigen assay and immunoblot analysis
of virus particles using Flag antibodies, it was estimated
that the ratio of Gag to Vpr was in the range of 150–200:1
when Vpr was expressed by HIV-1 proviral DNA. A much
higher level of incorporation (5–7:1 for Gag to Vpr) was
noted when Vpr was expressed in trans through an
efficient heterologous promoter.
RESULTS
Generation of recombinant plasmids containing
sequences encoding Gag-FL and Vpr-FL
and analysis of epitope-tagged protein
Gag and Vpr coding sequences were derived from
HIV-1 proviral DNA (NL4-3). The sequences correspond-
ing to the Flag epitope (DYKDDDDK) were added to the
39 end of the Vpr and Gag followed by a termination
codon using the PCR method. The Gag-FL coding se-
quences were bounded by EcoRI and XhoI enzyme sites
at the 59 and 39 end, respectively. Similarly, Vpr-FL coding
sequences were bounded by HindIII and XhoI enzyme
recognition sites. The Gag-FL and Vpr-FL sequences
were cloned into pCDNA3 vector, which consists of cy-
tomegalovirus immediate-early and T7 promoter up-
stream and bovine growth hormone poly(A)1 signal se-
uences downstream of the coding sequences. On clon-
ng, the integrity of the sequences was determined by
NA sequence analysis. Similar strategy was used to
enerate Gag-Vpr-FL in which Vpr-FL sequences were
used in frame to the 39 end of Gag.
Because the recombinant plasmids containing Gag-FL
nd Vpr-FL coding sequences have the T7 promoter, an
G
rn vitro transcription coupled translation system was
sed to analyze the protein. The synthesized proteins
ere tested with respective antibodies. Such an analysis
howed that Gag-FL protein was detected from sera from
IV-1-infected individuals and the corresponding bands
ere not present in the control where only vector DNA
as used. The same protein was also detected by using
ommercially available polyclonal antibodies against the
lag epitope. Consistent with the data obtained regard-
ng Gag-FL, antibodies against Flag epitope reacted with
he Vpr-FL. Furthermore, in vitro translated Gag-FL and
ag-Vpr-FL proteins showed bands of similar intensities
n Western blot analysis, implying equal accessibility of
lag epitope to antibodies in the context of Gag and Vpr
data not shown).
xpression of epitope-tagged proteins (Gag-FL and
pr-FL) in cells and incorporation of Vpr-FL
nto virus-like particles
For this purpose, we used recombinant vaccinia virus
xpressing T7 polymerase as described previously (Se-
io et al., 1997). HeLa cells, plated at a density of 2.5 3
06 per 100-mm Petri dish, were infected with the recom-
inant vaccinia virus the next day for 1 h. The cells were
ashed, and the plasmid DNAs were transfected either
lone or in combination into cells by using Lipofectin.
pproximately 40–45 h posttransfection, the culture su-
ernatant and the cells were collected separately. On
ysis of the cells, an aliquot was analyzed for the expres-
ion of Gag-FL and Vpr-FL. As observed with the in vitro
ynthesized proteins, antibodies against Flag epitope
etected Gag-FL and Vpr-FL (Fig. 1A). To determine the
ncorporation of Vpr-FL into virus-like particles, the cul-
ure supernatant was concentrated by centrifugation us-
ng the Amicon p30 column. The virus particles were
ysed, and the Gag-FL and Vpr-FL were tested by immu-
oblot analysis. The results indicated that transfection of
ag-FL resulted in the release of viral particles and that
pr-FL was observed in the supernatant only in associ-
tion with Gag (Fig. 1B).
ensitivity of the epitope-tag approach
The quantification of nonstructural proteins present in
he virus particles is generally carried out with the pro-
ein of interest expressed in a prokaryotic system, fol-
owed by purification of the protein for its use as a
tandard in the immunoblot analysis. However, such an
pproach for this study may still require the use of
ifferent antibodies to characterize the extent of incor-
oration of Vpr in relation to Gag into the virus particles.
ecause the affinity of the antibodies generally varies for
he respective proteins, which may complicate the inter-
retation of the data, we decided to generate Vpr-FL and
ag-FL using Flag epitope for quantitative assays. We
easoned that the availability of a sensitive ELISA assay
I
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366 SINGH ET AL.for the quantification of viral antigen in combination with
immunoblot analysis using Flag antibodies may provide
sufficient sensitivity to examine the ratio of Gag to Vpr in
the virus particles.
The proviral DNA NL4-3 and NL-Gag-FL (Fig. 2) were
independently transfected into RD cells. The virus parti-
cles released into the medium were collected at the end
of 5 days posttransfection. Immunoblot analysis using
antibodies against Flag epitope detected as little as 6 pg
of p24 antigen equivalent of virus particles on the sepa-
ration of proteins on SDS–PAGE (Figs. 3A and 3B). The
extent of reactivities of Flag epitope antibodies to differ-
ent concentration of proteins suggests that the approach
considered here has the desired sensitivity.
Determination of the ratio of Gag to Vpr in the virus
particles
The specific incorporation of Vpr into the virus parti-
cles directed by HIV-1 is a prerequisite for determining
the ratio of Gag to Vpr in the virus particles. The possi-
bility that nonspecific association of Vpr with contami-
nating vesicles in the virus preparation may lead to a
wrong estimation with respect to Vpr was considered. To
rule this out, we used wild-type and mutant Vpr-contain-
ing substitutions in helical domain I region in cotrans-
fection experiments with HIV-1 proviral DNA lacking Vpr
FIG. 1. Expression of Gag-FL and Vpr-FL in cells. Vaccinia virus-
infected cells were transfected with the respective plasmid DNA either
alone or in combination. Immunoblot analysis of the cell lysate (A) and
virus-like particles (B) was carried out using Flag antibodies. M, mo-
lecular weight markers (kDa); lane 1, pCDNA3; lane 2, Vpr-FL; lane 3,
Gag-FL; and lane 4, Gag-FL 1 Vpr-FL.expression. The immunoblot analysis of virus particles
showed that incorporation was observed only for wild-
m
ptype Vpr and not for mutant Vpr under the conditions
used in our experiments (data not shown). To obtain
information regarding the number of molecules of Vpr
present in the virus particles, we decided to use an
epitope-tagged Vpr in combination with and without an
epitope-tagged Gag. The modified NL4-3 proviral DNA
containing Vpr-FL (Fig. 2) was transfected into RD cells.
The virus particles released into the medium were har-
vested and quantified by p24 antigen assay, and immu-
noblot analysis was carried out using Flag antibodies.
The results (Fig. 4A) indicate that Vpr-FL can be detected
in the virus particles using viral lysate. In the context of
NL-Vpr-FL proviral DNA, only Vpr has the Flag epitope. In
an effort to generate information regarding the ratio of
Gag to Vpr in the virus particles, we used HIV-1 proviral
DNA in which both the Gag and Vpr have the Flag
epitope (Fig. 2). Hence, the analysis of virus particles
using Flag antibodies may shed light on the relative
amount of each protein present in the virus particles. The
results generated with this approach may show two
possible scenarios. First, an equal amount of Gag to Vpr
in the virus particles would yield bands of similar inten-
sities at Pr55 (Gag) and p14 (Vpr). Second, a differential
amount of Vpr in relation to Gag would yield an intense
band at Pr55 and a weak signal at p14. The immunoblot
analysis of virus particles derived from transfection of
NL-GV-FL revealed an altered ratio of Gag to Vpr in the
range of 150–200:1 (Fig. 4B). Because Vpr-FL in HIV-1
proviral DNA is expressed as a late protein, it is likely
that the level of incorporation may be due to the low level
of Vpr-FL present in the cells. To test this, it was impor-
tant to examine the extent of incorporation of Vpr-FL into
the virus particles when Vpr-FL was expressed in trans.
Toward this goal, cotransfection of NL-Gag-FL and
Vpr-FL expression plasmid into RD cells was carried out,
and the viral particles were subjected to immunoblot
analysis. The results showed that Vpr-FL, expressed in
trans, is incorporated into the virus particles at a higher
level than Vpr-FL expressed in the context of the proviral
DNA (Fig. 5). The ratio of Gag to Vpr was in the range of
5–7:1 in several independent experiments when only
Pr55 band was considered for estimation. The inclusion
of bands reactive to Flag antibodies below Pr55 showed
a ratio in the range of 11–14:1.
DISCUSSION
Among retroviruses, members of the lentivirus sub-
family exhibit a unique feature of incorporation of non-
structural proteins of viral origin into virus particles sim-
ilar to that of several DNA viruses (Fields et al., 1996).
nterestingly, HIV-1 has been shown to contain three
onstructural proteins in the virus particles: Vif, Vpr, and
ef (Cullen, 1998; Levy, 1998). The precise number of
olecules present in the virus particles has been re-
orted only for Vif (5–75 molecules) and Nef (5–20 mol-
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367STOICHIOMETRY OF VIRAL PROTEINSecules) (Camaur and Trono, 1996; Liu et al., 1995; Simon
et al., 1998; Welker et al., 1996). The number of molecules
f Vpr present in a virion is not clear. Currently, there are
onflicting data indicating that the number of Vpr mole-
ules may be similar to that of RT molecules derived from
he Gag-Pol precursor protein (Kobinger et al., 1998) and
ay also be similar to that of Gag (Cohen et al., 1990).
HIV-2/simian immunodeficiency virus particles contain a
protein known as Vpx, which is related to Vpr (Tristem et
al., 1992), and studies showed that Vpx is present in the
virus particles in quantities similar to that of p27 (Hen-
derson et al., 1988).
The virion-specific incorporation of HIV-1 nonstructural
proteins into virus particles has led to the suggestion
that these molecules can be explored to develop antiviral
agents against lentiviruses, as well as analytical tools to
dissect the events associated with the HIV-1 life-cycle
(Fletcher et al., 1997; Kobinger et al., 1998; Okui et al.,
998; Serio et al., 1997; Wu et al., 1996, 1997). To further
evelop this strategy, it would be desirable to know the
elative number of Vpr molecules present in the virus
FIG. 2. Schematic representation of HIV-1 proviral DNA (NL4-3) co
cleavage sites used for cloning chimeric Vpr and Gag containing Flagarticles. The report presented here provides an unique
pproach to quantify the proteins present in the virus
m
Tarticles. The experimental system that we used takes
dvantage of the addition of Flag epitope on both the
ag and Vpr. In combining the p24 antigen assay to
uantify Gag and immunoblot analysis using Flag anti-
odies, an attempt was made to determine the ratio of
ag to Vpr in the virion. The assay that has been rou-
inely used to determine the number of molecules of
onstructural versus structural proteins in the virus par-
icles requires generation of the candidate protein using
bacterial expression system for use as a standard in
he immunoblot analysis (Liu et al., 1995). Kobinger et al.
1998) recently reported that the number of molecules of
pr incorporated into the virus particles is similar to the
umber of RT molecules. This estimation was based on
enerating radiolabeled virus particles by incubating the
ells with 35S-methionine. The viral proteins were sub-
ected to immunoprecipitation by using antibodies spe-
ific to Vpr and RT and analyzed after SDS–PAGE. By
aking into account the number of methionine residues
resent in RT and Vpr, the signal intensity of the respec-
ive protein in the autoradiogram was analyzed to esti-
Vpr, Vpr-FL, Gag-FL, and Gag-FL 1 Vpr-FL. The restriction enzyme
e sequences are indicated at the top.ate the number of Vpr molecules in the virus particles.
hese approaches assume that the affinity of the anti-
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368 SINGH ET AL.bodies for the candidate proteins remains the same. The
use of Flag epitope on both Gag and Vpr proteins, in our
opinion, is advantageous because the same epitope on
both proteins eliminates the differential affinity generally
observed when using different antibodies and provides
an accurate molecule-to-molecule comparison.
The Flag epitope-tagging approach was successful in
obtaining the number of Vpr molecules present in the
virus particles, which varies according to the mode (cis
or trans) of expression of Vpr. The ratio of Gag to Vpr is
found to be in the range of 150–200:1. It is assumed that
there are 2750 molecules of Gag present per virion
(Arthur et al., 1992). Considering this, it is likely that each
FIG. 3. (A) Immunoblot analysis of virus particles using antibodies
gainst Flag epitope. Different concentrations of viral lysate, based on
24 antigen values, were subjected to the analysis after SDS–PAGE. M,
olecular weight markers (kDa); lanes 1–6, 192, 96, 48, 24, 12, and 6pg
24 antigen equivalent of viral lysate. (B) Densitometric analysis of
ag-FL in the virus particles. Chemiluminescence intensity of each
and was plotted against p24 antigen values.
FIG. 4. Immunoblot analysis of virus particles using antibodies
against Flag epitope. (A) Lane 1, NL-Vpr-FL; lane 2, virus particles
derived from cotransfection of NL-DVpr 1 Vpr-FL. (B) Quantitative
analysis of the ratio of Gag to Vpr in the virus particles directed by
NL-GV-FL. Vpr-FL is expressed in the context of HIV-1 proviral DNA.
Lanes 1–3, 50, 5, and 0.5 ml of viral lysate. Virus particles derived from
NL4-3 and NL-DVpr did not show the corresponding Vpr-FL band.virion may contain approximately 14–18 molecules of Vpr
as shown by densitometric analysis. It is to be noted that
the ratio 150–200:1 is only for the virus particles directed
by HIV-1 proviral DNA containing both Gag-FL and Vpr-
FL. As Vpr is subjected to regulation by Rev, the low
incorporation of Vpr into virus particles may be due to the
low amount of Vpr present in cells. Further, we also
examined whether the trans expression of Vpr affects the
efficiency of incorporation of Vpr into the virus particles.
This was addressed by cotransfection of modified HIV-1
proviral DNA lacking the ability to express Vpr (NL-Gag-
FL) and Vpr-FL expression plasmid in cells. The expres-
sion of Vpr in trans resulted in an enhancement in the
incorporation of Vpr into the virus particles with 392–550
Vpr molecules per virion. The estimated number of mol-
ecules of Vpr present in the virus particles in this study is
in disagreement with earlier studies (Cohen et al., 1990;
Kobinger et al., 1998). The overestimation with regard to
the number of molecules of Vpr present in the virus
particles reported earlier, in our view, may stem from the
methodologies used for evaluation. Because our method
uses an epitope-tag approach, we have also considered
the possibility that the addition of a tag may be detrimen-
tal to the virion incorporation phenotype of Vpr. Immuno-
blot analysis of virus particles derived from cotransfec-
tion of NLDVpr proviral DNA with either wild-type Vpr or
Vpr-FL expression plasmid showed bands with similar
reactivities to antibodies against Vpr (data not shown),
implying that the addition of Flag epitope did not interfere
with the virion incorporation of Vpr. Furthermore, the
presence of a similar amount of Vpr-FL in the virus-like
particles assembled by Gag and Gag-FL also supports
the above conclusion (data not shown). Hence, the re-
sults presented here suggest that one of the limiting
factors for the extent of incorporation of Vpr may be the
expression level of Vpr as noted for Vif (Simon et al.,
1998), and extrapolation of the data from the analysis of
virus particles generated through expression of Vpr in
FIG. 5. Quantitative analysis of the ratio of Gag to Vpr in the virus
particles when Vpr expression was directed in trans by a heterologous
promoter. Cotransfection of NL-Gag-FL and Vpr-FL expression plasmid
was carried out to derive the virus particles. On the addition of chemi-
luminescent substrate, the blot was exposed for 15 min (A) or 30 min
(B). Lane 1, NL-DVpr 1 Vpr-FL; lane 2, NL-DVpr; lane 3, NL-Gag-FL 1
Vpr-FL (30 ml of virus lysate); and lane 4, NL-Gag-FL 1 Vpr-FL (50 ml of
virus lysate).trans as opposed to its expression in cis should be made
with caution.
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369STOICHIOMETRY OF VIRAL PROTEINSThe differential level of Vpr and Gag present in the
virus particles may provide clues to understanding the
mechanism or mechanisms underlying the incorporation
of Vpr into the virus particles. Earlier studies by Lavallee
et al. (1994) showed an interaction between Vpr and Gag
in the infected cells. It should also be noted that specific
interaction of Vpr with p17 matrix (Sato et al., 1996) and
nucleocapsid p7 (de Rocquigny et al., 1997) has been
documented. It is not clear whether these interactions
exist in the context of the precursor Pr55 Gag and pro-
vide help for the incorporation of Vpr into the virus par-
ticles. Because the incorporation of Vpr into virus parti-
cles can be achieved through the transfer of the car-
boxyl-terminal p6 domain of Gag to heterologous
Gag-directed virus particles (Kondo et al., 1995), it is also
likely that a specific interaction between the p6 domain
and Vpr is possible. The quantitative data regarding the
amount of Vpr incorporation into virus-like particles di-
rected by p55 Gag versus heterologous virus particles
containing only the p6 may provide information regarding
the mechanism. This quantitative study further demon-
strates that Vpr can be used to develop antiviral agents
targeting virus maturation and can be used as a tool to
analyze the events associated with virus morphogene-
sis.
MATERIALS AND METHODS
Construction of recombinant plasmids encoding
Gag-FL and Vpr-FL and cloning of sequences
corresponding to epitope-tagged Gag
and Vpr into HIV-1 proviral DNA
Cloning of wild-type Gag and Vpr was carried out
using the pCDNA3 expression vector as described pre-
viously (Mahalingam et al., 1995). For the generation of
chimeric proteins containing Flag epitope, sequences
corresponding to the epitope (DYKDDDDK residues)
were incorporated in the 39 primer. The primers used to
generate Gag-FL were GACTGTTAAGTGTTTCAATTG
[Apa(1)] located upstream of ApaI restriction enzyme
cleavage site and CCCCCCTCGAGCTACTT-
GTCATCGTCGTCCTTGTAGTCTTGTGACGAGGGGTCGCT
[Gag-FL(2)] corresponding to the 39 end of Gag coding
sequences followed by Flag and XhoI restriction enzyme
cleavage site sequences. Primers TCTAGAAGCTTGC-
CGCCACCATGGAACAAGCCCCAGAAGAC [HKVpr(1)]
corresponding to HindIII restriction enzyme cleavage
site, kozak consensus, and 59 end of Vpr coding se-
quences and CCCCCCTCGAGCTACTTGTCATCGTCGT-
CCTTGTAGTCGGATCTACTGGCTCCTT [Vpr-FL(2)] rep-
resenting the 39 end of Vpr coding sequences followed
by Flag and XhoI restriction enzyme cleavage site se-
quences were used to generate Vpr-FL. For the construc-
tion of Gag-Vpr-FL, the individual PCRs were initiated
with Apa(1) and TTCTGGGGCTTGTTCCATTTGTGACGA-
GGGGTCGCTGCC [Gag-Vpr(2)] to amplify the 39 end of
a
dGag and to generate Vpr-FL using the primers ATGGAA-
CAAGCCCCAGAAGAC [Vpr(1)] and Vpr-FL(2). The
DNAs derived from both reactions were purified, mixed,
and amplified by using Apa(1) and VprFL(2) primers.
The amplified DNA was digested with ApaI and XhoI
estriction enzymes and ligated to the Gag clone cleaved
ppropriately.
Gag-FL and Vpr-FL sequences were introduced into
IV-1 NL4-3 proviral DNA. The schematic representation
f the proviral DNAs used is shown in Fig. 2. The proviral
NA designated NLDVpr lacks Vpr expression due to a
rameshift mutation (close to the EcoRI recognition site)
n the coding sequences. To avoid disruption of the
verlap of vpr and tat at the 39 end, the unique EcoRI and
alI restriction endonuclease cleavage sites were used
o introduce the 39 end of chimeric Vpr from the recom-
inant plasmid to generate NL-Vpr-FL. Similarly, the 39
nd fragment generated by using ApaI from the Gag-FL
lasmid was ligated to NL-DVpr cleaved with ApaI en-
yme to generate NL-Gag-FL. The generation of NL-GV-
L, containing Gag-FL and Vpr-FL, used NL-Vpr-FL plas-
id to introduce the Gag-FL 39 end fragment at the ApaI
ite.
n vitro transcription/translation and
adioimmunoprecipitation analysis of proteins
The coupled T7 transcription/translation system (Pro-
ega, Madison, WI) was used to characterize the ex-
ression of the recombinant clones. Incubation condi-
ions were followed according to manufacturer’s instruc-
ions. Radioimmunoprecipitation analysis of in vitro
ranslated proteins was carried out using polyclonal sera
o Gag, Vpr, and Flag epitope (Serio et al., 1997).
xpression and incorporation of Vpr-FL into
irus-like particles
To assess the expression of Vpr-FL and Gag-FL in
ells and incorporation of Vpr-FL into virus-like particles,
e used the vaccinia virus T7 polymerase expression
ystem. Vpr-FL and Gag-FL expression plasmids were
ransfected alone and in combination into HeLa cells
fter infection with vaccinia virus expressing T7 polymer-
se. Cell lysates and culture supernatants were sub-
ected to immunoblot analysis as described previously
Serio et al., 1997).
eneration of virus particles directed by HIV-1
roviral DNA
HIV-1 proviral DNA (wild type and modified in Gag and
pr coding sequences) was transfected into RD cells
ATCC CCL 136, American Type Culture Collection, Rock-
ille, MD) as described previously (Nagashunmugam et
l., 1992). Virus particles released into the culture me-
ium were harvested 120 h posttransfection and quanti-
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370 SINGH ET AL.fied by p24 antigen assay with an ELISA (Organon
Teknika, Durham, NC).
Immunoblot analysis
Virus-containing culture supernatants were precleared
for 10 min at 10,000 rpm and subjected to sucrose den-
sity gradient centrifugation (Serio et al., 1997). Virus pel-
lets were lysed in lysis buffer (62.5 mM Tris–HCl, pH 6.8,
0.2% SDS, 1% b-mercaptoethanol, and 10% glycerol).
amples were normalized on the basis of p24 antigen
alues and were run on 10% or 16% SDS–PAGE before
ransfer to nitrocellulose membrane. Membranes were
hen blocked in TBS (20 mM Tris, 500 mM NaCl, pH 7.5)
ontaining 5% (w/v) nonfat dry milk (Bio-Rad, Hercules,
A). Subsequent incubations with primary (anti-Flag M2;
:1000) (Eastman Kodak Company, New Haven, CT) and
econdary antisera [anti-mouse IgG (H&L) AP conjugate;
:3000] (Promega) were performed in TTBS (TBS contain-
ng 0.05% Tween-20). Each incubation was followed by
everal washings in TTBS. The blot was then incubated
ith Western blue detection reagent, or CDP-Star (Pro-
ega) was used as the chemiluminescent substrate in a
onradioactive detection system.
uantification by densitometry
The intensity of the bands obtained through immuno-
lot analysis was used for determination of the ratio of
ag to Vpr. Blots were scanned and densitometric anal-
sis was performed using the Molecular Dynamics Im-
geQuant program as described previously (Serio et al.,
999).
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